losartan and Anemia
losartan has been researched along with Anemia in 12 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Anemia: A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "Losartan is a safe, effective long-term treatment for hypertension or posttransplant erythrocytosis (PTE) in renal transplant recipients." | 7.73 | Anemia due to losartan in hypertensive renal transplant recipients without posttransplant erythrocytosis. ( Cift, A; Dilek, K; Ersoy, A; Ersoy, C; Kahvecioglu, S, 2005) |
| "High-dose losartan increases rHuEPO requirement and should be reserved for dialysis patients with hypertension uncontrollable with other antihypertensive medications." | 5.10 | The effect of high dose losartan on erythropoietin resistance in patients undergoing haemodialysis. ( Bilen, H; Cetinkaya, R; Keles, S; Odabas, AR; Selcuk, Y, 2003) |
| "Losartan is a safe, effective long-term treatment for hypertension or posttransplant erythrocytosis (PTE) in renal transplant recipients." | 3.73 | Anemia due to losartan in hypertensive renal transplant recipients without posttransplant erythrocytosis. ( Cift, A; Dilek, K; Ersoy, A; Ersoy, C; Kahvecioglu, S, 2005) |
| "Arterial hypertension significantly decreased after the introduction of losartan (p = 0." | 3.72 | Renoprotective effects of losartan in renal transplant recipients. Results of a retrospective study. ( Anaya, F; Campistol, JM; Del Castillo, D; Esforzado, N; Iñigo, P; Navarro, MD; Oppenheimer, F; Saracho, R, 2003) |
| "Diabetic nephropathy is the leading cause of end-stage renal disease (ESRD)." | 2.71 | Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. ( Brenner, BM; Keane, WF; Mohanram, A; Shahinfar, S; Toto, RD; Zhang, Z, 2004) |
| "Hemodialysis patients have uremic dyslipidemia, represented by elevated serum intermediate-density lipoprotein cholesterol (IDL-C) levels, and an increased cardiovascular mortality rate." | 2.71 | Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients. ( Furukawa, T; Hayashi, M; Homma, K; Ichihara, A; Kaneshiro, Y; Kanno, Y; Saruta, T; Takemitsu, T; Takenaka, T; Yoshizawa, M, 2005) |
Research
Studies (12)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (33.33) | 18.2507 |
| 2000's | 7 (58.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Aung, TKK | 1 |
| Chuah, TY | 1 |
| Chua, MWJ | 1 |
| Odabas, AR | 1 |
| Cetinkaya, R | 1 |
| Selcuk, Y | 1 |
| Keles, S | 1 |
| Bilen, H | 1 |
| Iñigo, P | 1 |
| Campistol, JM | 1 |
| Saracho, R | 1 |
| Del Castillo, D | 1 |
| Anaya, F | 1 |
| Esforzado, N | 1 |
| Navarro, MD | 1 |
| Oppenheimer, F | 1 |
| Mohanram, A | 2 |
| Zhang, Z | 2 |
| Shahinfar, S | 2 |
| Keane, WF | 1 |
| Brenner, BM | 1 |
| Toto, RD | 2 |
| Ichihara, A | 1 |
| Hayashi, M | 1 |
| Kaneshiro, Y | 1 |
| Takemitsu, T | 1 |
| Homma, K | 1 |
| Kanno, Y | 1 |
| Yoshizawa, M | 1 |
| Furukawa, T | 1 |
| Takenaka, T | 1 |
| Saruta, T | 1 |
| Ersoy, A | 1 |
| Kahvecioglu, S | 1 |
| Ersoy, C | 1 |
| Cift, A | 1 |
| Dilek, K | 1 |
| Lyle, PA | 1 |
| Schwarzbeck, A | 1 |
| Wittenmeier, KW | 1 |
| Hällfritzsch, U | 1 |
| Lang, SM | 2 |
| Schiffl, H | 2 |
| Kato, A | 1 |
| Takita, T | 1 |
| Furuhashi, M | 1 |
| Takahashi, T | 1 |
| Maruyama, Y | 1 |
| Hishida, A | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Renal Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes Mellitus and Nephropathy[NCT00308347] | Phase 3 | 1,513 participants (Actual) | Interventional | 1996-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Trials
7 trials available for losartan and Anemia
| Article | Year |
|---|---|
The effect of high dose losartan on erythropoietin resistance in patients undergoing haemodialysis.
Topics: Adult; Amlodipine; Anemia; Angiotensin Receptor Antagonists; Antihypertensive Agents; Dose-Response | 2003 |
Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy.
Topics: Aged; Anemia; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Pr | 2004 |
Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients.
Topics: Aged; Anemia; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Blo | 2005 |
The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes.
Topics: Aged; Anemia; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropat | 2008 |
Losartan and anaemia of end-stage renal disease.
Topics: Anemia; Antihypertensive Agents; Erythropoietin; Humans; Hypertension; Kidney Failure, Chronic; Losa | 1998 |
Angiotensin-converting enzyme inhibitors but not angiotensin II AT 1 receptor antagonists affect erythropoiesis in patients with anemia of end-stage renal disease.
Topics: Anemia; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 1999 |
No effect of losartan on response to erythropoietin therapy in patients undergoing hemodialysis.
Topics: Anemia; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Drug Interactions; Erythr | 2000 |
Other Studies
5 other studies available for losartan and Anemia
| Article | Year |
|---|---|
More Than Meets the Eye: A Patient with Hand Swelling and Newly Diagnosed Diabetes Mellitus.
Topics: Aged; Amlodipine; Anemia; Antihypertensive Agents; Blood Sedimentation; C-Reactive Protein; Diabetes | 2021 |
Renoprotective effects of losartan in renal transplant recipients. Results of a retrospective study.
Topics: Anemia; Antihypertensive Agents; Cough; Creatinine; Female; Follow-Up Studies; Humans; Hyperkalemia; | 2003 |
Anemia due to losartan in hypertensive renal transplant recipients without posttransplant erythrocytosis.
Topics: Adult; Anemia; Antihypertensive Agents; Body Mass Index; Calcium Channel Blockers; Creatinine; Eryth | 2005 |
Anaemia in dialysis patients as a side-effect of sartanes.
Topics: Anemia; Antihypertensive Agents; Biphenyl Compounds; Hemoglobins; Humans; Irbesartan; Kidney Transpl | 1998 |
Anaemia due to ACE inhibitors and losartan in patients with renal failure.
Topics: Anemia; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Clinical Trial | 1999 |